KNIGHT THERAPEUTICS INC (GUD.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:GUD - CA4990531069 - Common Stock
GUD.CA Key Statistics, Chart & Performance
The current stock price of GUD.CA is 5.98 CAD. In the past month the price decreased by -1.48%. In the past year, price increased by 9.12%.
GUD.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to GUD.CA. When comparing the yearly performance of all stocks, GUD.CA turns out to be only a medium performer in the overall market: it outperformed 43.67% of all stocks.
GUD.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GUD.CA. GUD.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GUD.CA Financial Highlights
Over the last trailing twelve months GUD.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 93.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| Debt/Equity | 0.11 |
GUD.CA Forecast & Estimates
10 analysts have analysed GUD.CA and the average price target is 8.03 CAD. This implies a price increase of 34.26% is expected in the next year compared to the current price of 5.98.
For the next year, analysts expect an EPS growth of -423.2% and a revenue growth 20.19% for GUD.CA
GUD.CA Ownership
GUD.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.95 | 3.84B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.59B | ||
| CRON.CA | CRONOS GROUP INC | 24.4 | 1.40B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.16 | 887.82M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 5.12 | 634.32M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 630.07M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 562.00M | ||
| TSND.CA | TERRASCEND CORP | N/A | 423.49M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 16.91 | 394.76M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 331.70M | ||
| HITI.CA | HIGH TIDE INC | N/A | 314.10M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 302.24M |
Related stock screener links
About GUD.CA
Company Profile
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The company is headquartered in Montreal, Quebec and currently employs 745 full-time employees. The company went IPO on 2014-02-28. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The company finances other life sciences companies and secures product distribution rights for Canada and select international markets. The firm monitors investments in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. The company develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by the Company such as Exelon and Impavido.
Company Info
KNIGHT THERAPEUTICS INC
3400 De Maisonneuve Blvd W
MONTREAL QUEBEC H3Z 3B8 CA
CEO: Jonathan Ross Goodman
Employees: 745
Phone: 15144844483
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
Can you describe the business of KNIGHT THERAPEUTICS INC?
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The company is headquartered in Montreal, Quebec and currently employs 745 full-time employees. The company went IPO on 2014-02-28. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The company finances other life sciences companies and secures product distribution rights for Canada and select international markets. The firm monitors investments in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. The company develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by the Company such as Exelon and Impavido.
What is the current price of GUD stock?
The current stock price of GUD.CA is 5.98 CAD. The price increased by 1.18% in the last trading session.
Does GUD stock pay dividends?
GUD.CA does not pay a dividend.
How is the ChartMill rating for KNIGHT THERAPEUTICS INC?
GUD.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the GICS sector and industry of GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) operates in the Health Care sector and the Pharmaceuticals industry.
How many employees does KNIGHT THERAPEUTICS INC have?
KNIGHT THERAPEUTICS INC (GUD.CA) currently has 745 employees.
What is the market capitalization of GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) has a market capitalization of 593.75M CAD. This makes GUD.CA a Small Cap stock.